United Therapeutic (UTHR) 111.16 $UTHR
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (unch), INVA: 11.64 (+0.26), GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 23.25 (-0.24), UTHR: 111.16 (+1.58), AZN: 30.11 (unch)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 111.16 (+1.58), AMRN: 2.19 (+0.02), DEPO: 18.77 (+0.01), IONS: 25.36 (+0.22)
United Therapeutics Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.58 to a high of $121.69. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $119.59 on volume of 230,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 111.16 (+1.58)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Wed May 25, 3:38AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $116.62 on volume of 639,000 shares, below average daily volume of 888,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
UTHR: 111.16 (+1.58)
United Therapeutics Partnering Deals and Alliances 2010 to 2016
PR Newswire - Tue May 24, 3:47PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
UTHR: 111.16 (+1.58)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 3.59% Gain
Comtex SmarTrend(R) - Fri May 13, 2:22PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.42 to a high of $113.33. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $112.99 on volume of 253,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 111.16 (+1.58)
Crosswind PR Issues Correction to May 9 Press Release
PRWeb - Tue May 10, 3:10PM CDT
Crosswind Media & PR issues the following correction to a press release issued May 9, 2016. The press release titled, "United Therapeutics Selects HCB Health as Agency of Record for Remodulin," was printed in error. This is now removed from online news sources and outlets. Crosswind Media & PR takes full responsibility for this error. This was not an error made by our client, HCB Health, nor the fault of PRWeb. Moreover, the press release was not reviewed or approved by United Therapeutics Corporation.
UTHR: 111.16 (+1.58)
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.42 (+0.14), GILD: 86.55 (+1.08), MRK: 59.35 (+0.57), UTHR: 111.16 (+1.58)
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 30.04 (+0.46), UTHR: 111.16 (+1.58), AEGR: 1.67 (+0.02)
United Therapeutics Falls 8.71% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Apr 28, 1:20PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.50 to a high of $109.03. Yesterday, the shares fell 8.7%, which took the trading range below the 3-day low of $116.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 111.16 (+1.58)
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 8.71%
Comtex SmarTrend(R) - Thu Apr 28, 1:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.50 to a high of $109.03. Yesterday, the shares fell 8.7%, which took the trading range below the 3-day low of $116.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 111.16 (+1.58)
What's Behind United Therapeutics' Slumping Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 11:03AM CDT
SOURCE: UNITED THERAPEUTICS CORPORATION What: After reporting first quarter financials that were shy of industry watcher's forecasts, shares of United Therapeutics Corporation were trading 10% lower at 11:30 a.m. EST Thursday. So what: ...
UTHR: 111.16 (+1.58)
United Therapeutics Corporation Announces Executive Leadership Changes
PR Newswire - Thu Apr 28, 5:05AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Roger Jeffs, Ph.D. has stepped down as the company's President and Co-Chief Executive Officer and David Zaccardelli, Pharm.D. has stepped down as the company's Executive Vice President and Chief Operating Officer. These departures will become effective June 26, 2016. In addition, Dr. Jeffs will not stand for re-election to the company's Board of Directors when his current term expires at the 2016 Annual Meeting of Shareholders, which is to be held on June 21, 2016. Dr. Jeffs will become a Senior Advisor to the company.
UTHR: 111.16 (+1.58)
United Therapeutics Corporation Reports First Quarter 2016 Financial Results
PR Newswire - Thu Apr 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2016.
UTHR: 111.16 (+1.58)
United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the Deutsche Bank 41st Annual Health Care Conference.
UTHR: 111.16 (+1.58), DB: 12.97 (+0.37)
SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings
GlobeNewswire - Mon Apr 25, 7:30AM CDT
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Decision to Institute the Inter Partes Review (IPR) proceeding against U.S. Patent No. 8,497,393 (the '393 patent), owned by United Therapeutics (Nasdaq:UTHR), is now publicly available. This patent relates to a process to further purify prostacyclin derivatives, such as treprostinil. Treprostinil is the active pharmaceutical ingredient used in United Therapeutics' Remodulin(R) and SteadyMed's lead drug candidate, Trevyent(R), for the treatment of Pulmonary Arterial Hypertension (PAH).
UTHR: 111.16 (+1.58), STDY: 3.37 (-0.01)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (unch), INVA: 11.64 (+0.26), GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 23.25 (-0.24), UTHR: 111.16 (+1.58), AZN: 30.11 (unch)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 111.16 (+1.58), AMRN: 2.19 (+0.02), DEPO: 18.77 (+0.01), IONS: 25.36 (+0.22)
United Therapeutics Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.58 to a high of $121.69. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $119.59 on volume of 230,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 111.16 (+1.58)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Wed May 25, 3:38AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $116.62 on volume of 639,000 shares, below average daily volume of 888,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
UTHR: 111.16 (+1.58)
United Therapeutics Partnering Deals and Alliances 2010 to 2016
PR Newswire - Tue May 24, 3:47PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
UTHR: 111.16 (+1.58)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 3.59% Gain
Comtex SmarTrend(R) - Fri May 13, 2:22PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.42 to a high of $113.33. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $112.99 on volume of 253,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 111.16 (+1.58)
Crosswind PR Issues Correction to May 9 Press Release
PRWeb - Tue May 10, 3:10PM CDT
Crosswind Media & PR issues the following correction to a press release issued May 9, 2016. The press release titled, "United Therapeutics Selects HCB Health as Agency of Record for Remodulin," was printed in error. This is now removed from online news sources and outlets. Crosswind Media & PR takes full responsibility for this error. This was not an error made by our client, HCB Health, nor the fault of PRWeb. Moreover, the press release was not reviewed or approved by United Therapeutics Corporation.
UTHR: 111.16 (+1.58)
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.42 (+0.14), GILD: 86.55 (+1.08), MRK: 59.35 (+0.57), UTHR: 111.16 (+1.58)
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 30.04 (+0.46), UTHR: 111.16 (+1.58), AEGR: 1.67 (+0.02)
United Therapeutics Falls 8.71% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Apr 28, 1:20PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.50 to a high of $109.03. Yesterday, the shares fell 8.7%, which took the trading range below the 3-day low of $116.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 111.16 (+1.58)
United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 8.71%
Comtex SmarTrend(R) - Thu Apr 28, 1:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.50 to a high of $109.03. Yesterday, the shares fell 8.7%, which took the trading range below the 3-day low of $116.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 111.16 (+1.58)
What's Behind United Therapeutics' Slumping Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 11:03AM CDT
SOURCE: UNITED THERAPEUTICS CORPORATION What: After reporting first quarter financials that were shy of industry watcher's forecasts, shares of United Therapeutics Corporation were trading 10% lower at 11:30 a.m. EST Thursday. So what: ...
UTHR: 111.16 (+1.58)
United Therapeutics Corporation Announces Executive Leadership Changes
PR Newswire - Thu Apr 28, 5:05AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Roger Jeffs, Ph.D. has stepped down as the company's President and Co-Chief Executive Officer and David Zaccardelli, Pharm.D. has stepped down as the company's Executive Vice President and Chief Operating Officer. These departures will become effective June 26, 2016. In addition, Dr. Jeffs will not stand for re-election to the company's Board of Directors when his current term expires at the 2016 Annual Meeting of Shareholders, which is to be held on June 21, 2016. Dr. Jeffs will become a Senior Advisor to the company.
UTHR: 111.16 (+1.58)
United Therapeutics Corporation Reports First Quarter 2016 Financial Results
PR Newswire - Thu Apr 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2016.
UTHR: 111.16 (+1.58)
United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the Deutsche Bank 41st Annual Health Care Conference.
UTHR: 111.16 (+1.58), DB: 12.97 (+0.37)
SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings
GlobeNewswire - Mon Apr 25, 7:30AM CDT
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Decision to Institute the Inter Partes Review (IPR) proceeding against U.S. Patent No. 8,497,393 (the '393 patent), owned by United Therapeutics (Nasdaq:UTHR), is now publicly available. This patent relates to a process to further purify prostacyclin derivatives, such as treprostinil. Treprostinil is the active pharmaceutical ingredient used in United Therapeutics' Remodulin(R) and SteadyMed's lead drug candidate, Trevyent(R), for the treatment of Pulmonary Arterial Hypertension (PAH).
UTHR: 111.16 (+1.58), STDY: 3.37 (-0.01)
